Cellular xenotransplantation

Current Opinion in Organ Transplantation

Volumn 14, Issue 2, 2009, Pages 168-174

  Poncelet, Alain J ^a,b   Denis, Dufrane ^a   Gianello, Pierre ^a  

^a UNIVERSITY OF LOUVAIN MEDICAL SCHOOL   (Belgium)

^b CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

Cellular therapy; Diabetes; Encapsulation; Heart failure; Swine; Xenotransplantation

Indexed keywords

ALPHA 1,3 GALACTOSYLTRANSFERASE;

BONE REGENERATION; CELL TRANSPLANTATION; ENCAPSULATION; ENZYME ACTIVITY; HEART FAILURE; HUMAN; HUNTINGTON CHOREA; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; INNATE IMMUNITY; INSULIN DEPENDENT DIABETES MELLITUS; LIVER CELL; LIVER FAILURE; MESENCHYMAL STEM CELL; NATURAL KILLER CELL; NERVE CELL; NONHUMAN; PANCREAS ISLET CELL; PARKINSON DISEASE; REVIEW; TISSUE REPAIR; TRANSGENIC PIG; XENOTRANSPLANTATION; ALLOTRANSPLANTATION; ANIMAL; BONE DISEASE; CELL SURVIVAL; GRAFT SURVIVAL; IMMUNOLOGY; MESENCHYMAL STEM CELL TRANSPLANTATION; PANCREAS ISLET TRANSPLANTATION; REGENERATIVE MEDICINE; SWINE; TRANSPLANTATION; TRANSPLANTATION TOLERANCE; XENOGRAFT;

ANIMALS; BONE DISEASES; CELL SURVIVAL; DIABETES MELLITUS, TYPE 1; GRAFT SURVIVAL; HEART FAILURE; HEPATOCYTES; HUMANS; HUNTINGTON DISEASE; ISLETS OF LANGERHANS TRANSPLANTATION; LIVER FAILURE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STEM CELLS; NEURONS; PARKINSON DISEASE; REGENERATIVE MEDICINE; SWINE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION TOLERANCE; TRANSPLANTATION, HETEROLOGOUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 67651071738     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e3283292522     Document Type: Review

References (115)

1. Kannel WB, Belanger AJ. Epidemiology of heart failure. Am Heart J 1991; 121:951-957.
2. MacIntyre K, Capewell S, Stewart S, et al. Evidence of improving prognosis in heart failure: trends in case fatality in 66 547 patients hospitalized between 1986 and 1995. Circulation 2000; 102:1126-1131.
3. Ho KK, Anderson KM, Kannel WB, et al. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation 1993; 88:107-115. (Pubitemid 23195439)
4. Beltrami AP, Urbanek K, Kajstura J, et al. Evidence that human cardiac myocytes divide after myocardial infarction. N Engl J Med 2001; 344:1750-1757. (Pubitemid 32497029)
5. Laflamme MA, Myerson D, Saffitz JE, Murry CE. Evidence for cardiomyocyte repopulation by extracardiac progenitors in transplanted human hearts. Circ Res 2002; 90:634-640. (Pubitemid 34640880)
6. Li RK, Mickle DA, Weisel RD, et al. Natural history of fetal rat cardiomyocytes transplanted into adult rat myocardial scar tissue. Circulation 1997; 96:II-86.
7. Min JY, Yang Y, Converso KL, et al. Transplantation of embryonic stem cells improves cardiac function in postinfarcted rats. J Appl Physiol 2002; 92:288-296. (Pubitemid 34670018)
8. Kim EJ, Li RK, Weisel RD, et al. Angiogenesis by endothelial cell transplantation. J Thorac Cardiovasc Surg 2001; 122:963-971.
9. Kocher AA, Schuster MD, Szabolcs MJ, et al. Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function 24. Nat Med 2001; 7:430-436.
10. Orlic D, Kajstura J, Chimenti S, et al. Bone marrow cells regenerate infarcted myocardium. Nature 2001; 410:701-705. (Pubitemid 32290358)
11. Wang JS, Shum-Tim D, Galipeau J, et al. Marrow stromal cells for cellular cardiomyoplasty: feasibility and potential clinical advantages. J Thorac Cardiovasc Surg 2000; 120:999-1005. (Pubitemid 30816141)
12. Min JY, Sullivan MF, Yang Y, et al. Significant improvement of heart function by cotransplantation of human mesenchymal stem cells and fetal cardiomyocytes in postinfarcted pigs. Ann Thorac Surg 2002; 74:1568-1575. (Pubitemid 35222642)
13. Scorsin M, Hagege AA, Marotte F, et al. Does transplantation of cardiomyocytes improve function of infarcted myocardium? Circulation 1997; 96:II-93.
14. Reyes M, Lund T, Lenvik T, et al. Purification and ex vivo expansion of postnatal human marrow mesodermal progenitor cells. Blood 2001; 98: 2615-2625.
15. Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999; 284:143-147. (Pubitemid 29282067)
16. Tse WT, Pendleton JD, Beyer WM, et al. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation 2003; 75:389-397.
17. Di Nicola M, Carlo-Stella C, Magni M, et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002; 99:3838-3843. (Pubitemid 34534559)
18. Le Blanc K, Tammik L, Sundberg B, et al. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol 2003; 57:11-20. (Pubitemid 38019084)
19. Rehman J, Traktuev D, Li J, et al. Secretion of angiogenic and antiapoptotic factors by human adipose stromal cells. Circulation 2004; 109:1292-1298. (Pubitemid 38372789)
20. Djouad F, Plence P, Bony C, et al. Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood 2003; 102:3837-3844. (Pubitemid 37409409)
21. Liu J, Lu XF, Wan L, et al. Suppression of human peripheral blood lymphocyte proliferation by immortalized mesenchymal stem cells derived from bone marrow of Banna minipig inbred-line. Transplant Proc 2004; 36:3272-3275. (Pubitemid 41126790)
22. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005; 105:1815-1822. (Pubitemid 40223708)
23. Min CK, Kim BG, Park G, et al. IL-10-transduced bone marrow mesenchymal stem cells can attenuate the severity of acute graft-versus-host disease after experimental allogeneic stem cell transplantation. Bone Marrow Transplant 2007; 39:637-645. (Pubitemid 46722844)
24. Meisel R, Zibert A, Laryea M, et al. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood 2004; 103:4619-4621. (Pubitemid 38745993)
25. Krampera M, Cosmi L, Angeli R, et al. Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells 2006; 24:386-398. (Pubitemid 44464808)
26. Sato K, Ozaki K, Oh I, et al. Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. Blood 2007; 109:228-234. (Pubitemid 46053063)
27. Chabannes D, Hill M, Merieau E, et al. A role for heme oxygenase-1 in the immunosuppressive effect of adult rat and human mesenchymal stem cells. Blood 2007; 110:3691-3694. (Pubitemid 350159638)
28. Selmani Z, Naji A, Zidi I, et al. Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3+ regulatory T cells. Stem Cells 2008; 26:212-222.
29. Nasef A, Mathieu N, Chapel A, et al. Immunosuppressive effects of mesenchymal stem cells: involvement of HLA-G. Transplantation 2007; 84:231-237. (Pubitemid 47205757)
30. Inoue S, Popp FC, Koehl GE, et al. Immunomodulatory effects of mesenchymal stem cells in a rat organ transplant model. Transplantation 2006; 81:1589-1595. (Pubitemid 43890897)
31. Badillo AT, Beggs KJ, Javazon EH, et al. Murine bone marrow stromal progenitor cells elicit an in vivo cellular and humoral alloimmune response. Biol Blood Marrow Transplant 2007; 13:412-422. This study, using well characterized population of murine bone marrow-derived MSC, demonstrates that in contrast to their in-vitro behavior, intraperitoneal injection of unstimulated MSCs elicited donor-specific cellular and humoral immune responses and decreased subsequent donor-specific skin graft survival.
32. Poncelet AJ, Vercruysse J, Saliez A, Gianello P. Although pig allogeneic mesenchymal stem cells are not immunogenic in vitro, intracardiac injection elicits an immune response in vivo. Transplantation 2007; 83:783-790. (Pubitemid 46569198)
33. Poncelet AJ, Nizet Y, Vercruysse J, et al. Inhibition of humoral response to allogeneic porcine mesenchymal stem cell with 12 days of tacrolimus. Transplantation 2008; 86:1586-1595.
34. Nakamura Y, Wang X, Xu C, et al. Xenotransplantation of long-term-cultured swine bone marrow-derived mesenchymal stem cells. Stem Cells 2007; 25:612-620. The authors hypothesized that extensively multipassaged swine MSCs would retain therapeutic potency in an acute myocardial infarction model. After 96 population doubling, there was no evidence of cytogenetic abnormalities. Using immunodeficient (nonobese diabetic/severe combined immunodeficient) mice, they show that a fraction of transplanted MSCs remained at least 4 weeks after transplantation, and left ventricular contractile function was significantly improved in transplanted hearts. Importantly, the study showed that few engrafted MSCs developed cardiomyocyte or endothelial cell markers, suggesting that the benefits of transplantation did not derive from structural contributions of engrafted MSCs. (Pubitemid 46354219)
35. Grinnemo KH, Mansson A, Dellgren G, et al. Xenoreactivity and engraftment of human mesenchymal stem cells transplanted into infarcted rat myocardium. J Thorac Cardiovasc Surg 2004; 127:1293-1300. (Pubitemid 38560590)
36. Grauss RW, van Tuyn J, Steendijk P, et al. Forced myocardin expression enhances the therapeutic effect of human mesenchymal stem cells after transplantation in ischemic mouse hearts. Stem Cells 2008; 26:1083-1093.
37. Meyerrose TE, De Ugarte DA, Hofling AA, et al. In vivo distribution of human adipose-derived mesenchymal stem cells in novel xenotransplantation models. Stem Cells 2007; 25:220-227.
38. Pelz O, Wu M, Nikolova T, et al. Duplex polymerase chain reaction quanti- fication of human cells in a murine background. Stem Cells 2005; 23:828-833. (Pubitemid 40791797)
39. Saito T, Kuang JQ, Bittira B, et al. Xenotransplant cardiac chimera: immune tolerance of adult stem cells. Ann Thorac Surg 2002; 74:19-24. (Pubitemid 34741999)
40. Krampera M, Glennie S, Dyson J, et al. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 2003; 101:3722-3729. (Pubitemid 36857965)
41. Artrip JH, Kwiatkowski P, Michler RE, et al. Target cell susceptibility to lysis by human natural killer cells is augmented by alpha(1,3)- galactosyltransferase and reduced by alpha(1,2)-fucosyltransferase. J Biol Chem 1999; 274: 10717-10722.
42. Inverardi L, Clissi B, Stolzer AL, et al. Human natural killer lymphocytes directly recognize evolutionarily conserved oligosaccharide ligands expressed by xenogeneic tissues. Transplantation 1997; 63:1318-1330. (Pubitemid 27212829)
43. Gojo S, Harper D, Down J, et al. Differential expression of Galalpha1,3Gal epitopes on fetal and adult porcine hematopoietic cells. Xenotransplantation 2002; 9:297-300. (Pubitemid 36358954)
44. Harrower TP, Richards A, Cruz G, et al. Alpha Gal is widely expressed in embryonic porcine stem cells and neural tissue. Neuroreport 2002; 13:481-485. (Pubitemid 34293195)
45. Spaggiari GM, Capobianco A, Becchetti S, et al. Mesenchymal stem cellnatural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood 2006; 107:1484-1490. (Pubitemid 43242385)
46. Sotiropoulou PA, Perez SA, Gritzapis AD, et al. Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells 2006; 24:74-85.
47. Kraitchman DL, Tatsumi M, Gilson WD, et al. Dynamic imaging of allogeneic mesenchymal stem cells trafficking to myocardial infarction. Circulation 2005; 112:1451-1461. (Pubitemid 41291771)
48. Muller-Ehmsen J, Krausgrill B, Burst V, et al. Effective engraftment but poor mid-term persistence of mononuclear and mesenchymal bone marrow cells in acute and chronic rat myocardial infarction. J Mol Cell Cardiol 2006; 41:876-884. (Pubitemid 44635568)
49. Mangi AA, Noiseux N, Kong D, et al. Mesenchymal stem cells modified with Akt prevent remodeling and restore performance of infarcted hearts. NatMed 2003; 9:1195-1201. (Pubitemid 37173705)
50. Shapiro AM, Lakey JR, Ryan EA, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000; 343:230-238.
51. Frank AM, Barker CF, Markmann JF. Comparison of whole organ pancreas and isolated islet transplantation for type 1 diabetes. Adv Surg 2005; 39:137-163. (Pubitemid 41737959)
52. Shapiro AM, Ricordi C, Hering BJ, et al. International trial of the Edmonton protocol for islet transplantation. N Engl J Med 2006; 355:1318-1330. (Pubitemid 44465460)
53. Ryan EA, Paty BW, Senior PA, et al. Five-year follow-up after clinical islet transplantation. Diabetes 2005; 54:2060-2069. (Pubitemid 40911269)
54. Prabhakaran S, Hering BJ. What strain of pig should be used? Xenotransplantation 2008; 15:83-86.
55. Rajotte RV. Isolation and assessment of islet quality. Xenotransplantation 2008; 15:93-95.
56. Kurz H. Physiology of angiogenesis. J Neurooncol 2000; 50:17-35.
57. Mendola JF, Conget I, Manzanares JM, et al. Follow-up study of the revascularization process of purified rat islet beta-cell grafts. Cell Transplant 1997; 6:603-612. (Pubitemid 28013623)
58. Menger MD, Jaeger S, Walter P, et al. Angiogenesis and hemodynamics of microvasculature of transplanted islets of Langerhans. Diabetes 1989; 38 (Suppl 1):199-201. (Pubitemid 19029279)
59. Patan S. Vasculogenesis angiogenesis as mechanisms of vascular network formation, growth and remodeling. J Neurooncol 2000; 50:1-15. (Pubitemid 32166287)
60. Vajkoczy P, Menger MD, Simpson E, Messmer K. Angiogenesis and vascularization of murine pancreatic islet isografts. Transplantation 1995; 60: 123-127.
61. Vajkoczy P, Olofsson AM, Lehr HA, et al. Histogenesis and ultrastructure of pancreatic islet graft microvasculature. Evidence for graft revascularization by endothelial cells of host origin. Am J Pathol 1995; 146:1397-1405.
62. Korsgren O, Jansson L. Discordant cellular xenografts revascularized in intermediate athymic hosts fail to induce a hyperacute rejection when transplanted to immunocompetent rats. Transplantation 1994; 57:1408-1411. (Pubitemid 24145595)
63. Moberg L. The role of the innate immunity in islet transplantation. Ups J Med Sci 2005; 110:17-55. (Pubitemid 40342459)
64. Nilsson B. The instant blood-mediated inflammatory reaction in xenogeneic islet transplantation. Xenotransplantation 2008; 15:96-98. (Pubitemid 351601127)
65. Ehrnfelt C, Kumagai-Braesch M, Uzunel M, Holgersson J. Adult porcine islets produce MCP-1 and recruit human monocytes in vitro. Xenotransplantation 2004; 11:184-194. (Pubitemid 38282269)
66. Johansson H, Lukinius A, Moberg L, et al. Tissue factor produced by the endocrine cells of the islets of Langerhans is associated with a negative outcome of clinical islet transplantation. Diabetes 2005; 54:1755-1762. (Pubitemid 40770765)
67. Contreras JL. Extrahepatic transplant sites for islet xenotransplantation. Xenotransplantation 2008; 15:99-101.
68. Soderlund J, Wennberg L, Castanos-Velez E, et al. Fetal porcine islet-like cell clusters transplanted to cynomolgus monkeys: an immunohistochemical study. Transplantation 1999; 67:784-791. (Pubitemid 29169121)
69. Kirchhof N, Shibata S, Wijkstrom M, et al. Reversal of diabetes in nonimmunosuppressed rhesus macaques by intraportal porcine islet xenografts precedes acute cellular rejection. Xenotransplantation 2004; 11:396-407. (Pubitemid 39128209)
70. Cantarovich D, Blancho G, Potiron N, et al. Rapid failure of pig islet transplantation in non human primates. Xenotransplantation 2002; 9: 25-35. (Pubitemid 36358221)
71. Buhler L, Deng S, O'Neil J, et al. Adult porcine islet transplantation in baboons treated with conventional immunosuppression or a nonmyeloablative regimen and CD154 blockade. Xenotransplantation 2002; 9:3-13. (Pubitemid 36358219)
72. Nishimaki T, Kano K, Milgrom F. Hanganutziu-Deicher antigen and antibody in pathologic sera and tissues. J Immunol 1979; 122:2314-2318. (Pubitemid 9185795)
73. Komoda H, Miyagawa S, Kubo T, et al. A study of the xenoantigenicity of adult pig islets cells. Xenotransplantation 2004; 11:237-246. (Pubitemid 38623060)
74. Auchincloss H Jr, Sachs DH. Xenogeneic transplantation. Annu Rev Immunol 1998; 16:433-470.
75. Rayat GR, Rajotte RV, Hering BJ, et al. In vitro and in vivo expression of Galalpha-(1,3)Gal on porcine islet cells is age dependent. J Endocrinol 2003; 177:127-135.
76. Bennet W, Sundberg B, Lundgren T, et al. Damage to porcine islets of Langerhans after exposure to human blood in vitro, or after intraportal transplantation to cynomolgus monkeys: protective effects of sCR1 and heparin. Transplantation 2000; 69:711-719. (Pubitemid 30174086)
77. Dor FJ, Cheng J, Alt A, et al. Gal alpha 1,3Gal expression on porcine pancreatic islets, testis, spleen, and thymus. Xenotransplantation 2004; 11:101-106. (Pubitemid 38160272)
78. Dufrane D, Goebbels RM, Guiot Y, Gianello P. Is the expression of Gal-alpha1,3Gal on porcine pancreatic islets modified by isolation procedure? Transplant Proc 2005; 37:455-457.
79. Dufrane D, Goebbels RM, Saliez A, et al. Six-month survival of microencapsulated pig islets and alginate biocompatibility in primates: proof of concept. Transplantation 2006; 81:1345-1353. (Pubitemid 43804557)
80. Komoda H, Miyagawa S, Omori T, et al. Survival of adult islet grafts from transgenic pigs with N-acetylglucosaminyltransferase-III (GnT-III) in cynomolgus monkeys. Xenotransplantation 2005; 12:209-216.
81. Rijkelijkhuizen JK, Haanstra KG, Wubben J, et al. T-cell-specific immunosuppression results in more than 53 days survival of porcine islets of langerhans in the monkey. Transplantation 2003; 76:1359-1368. (Pubitemid 37430724)
82. Sun Y, Ma X, Zhou D, et al. Normalization of diabetes in spontaneously diabetic cynomolgus monkeys by xenografts of microencapsulated porcine islets without immunosuppression. J Clin Invest 1996; 98:1417-1422. (Pubitemid 26322067)
83. Rood PP, Bottino R, Balamurugan AN, et al. Reduction of early graft loss after intraportal porcine islet transplantation in monkeys 19. Transplantation 2007; 83:202-210. (Pubitemid 46185211)
84. Hering BJ, Wijkstrom M, Graham ML, et al. Prolonged diabetes reversal after intraportal xenotransplantation of wild-type porcine islets in immunosuppressed nonhuman primates. Nat Med 2006; 12:301-303. (Pubitemid 43355076)
85. Cardona K, Korbutt GS, Milas Z, et al. Long-term survival of neonatal porcine islets in nonhuman primates by targeting costimulation pathways. Nat Med 2006; 12:304-306. (Pubitemid 43355077)
86. Bottino R, Cooper DK. Islet xenotransplantation: the pig-to-nonhuman primate model. Xenotransplantation 2008; 15:104-106. (Pubitemid 351601130)
87. Gangappa S, Larsen CP. Immunosuppressive protocols for pig-to-human islet transplantation: lessons from preclinical nonhuman primate models. Xenotransplantation 2008; 15:107-111. (Pubitemid 351601131)
88. Abstracts of the Joint Meeting of the International Xenotransplantation Association (IXA), the International Pancreas and Islet Transplant Association (IPITA), and the Cell Transplant Society (CTS), Minneapolis, Minnesota, USA, September 15-20, 2007. Xenotransplantation 2007; 14:375-549.
89. Elliott RB, Escobar L, Tan PL, et al. Live encapsulated porcine islets from a type 1 diabetic patient 9.5 yr after xenotransplantation. Xenotransplantation 2007; 14:157-161. (Pubitemid 46457454)
90. Valdes-Gonzalez RA, Dorantes LM, Garibay GN, et al. Xenotransplantation of porcine neonatal islets of Langerhans and Sertoli cells: a 4-year study. Eur J Endocrinol 2005; 153:419-427. (Pubitemid 41410499)
91. Elliott RB, Escobar L, Calafiore R, et al. Transplantation of micro- and macroencapsulated piglet islets into mice and monkeys. Transplant Proc 2005; 37:466-469. (Pubitemid 40459820)
92. Fink JS, Schumacher JM, Ellias SL, et al. Porcine xenografts in Parkinson's disease and Huntington's disease patients: preliminary results. Cell Transplant 2000; 9:273-278. (Pubitemid 30252692)
93. Dinsmore JH, Manhart C, Raineri R, et al. No evidence for infection of human cells with porcine endogenous retrovirus (PERV) after exposure to porcine fetal neuronal cells. Transplantation 2000; 70:1382-1389. (Pubitemid 30840105)
94. Armstrong RJ, Hurelbrink CB, Tyers P, et al. The potential for circuit reconstruction by expanded neural precursor cells explored through porcine xenografts in a rat model of Parkinson's disease. Exp Neurol 2002; 175: 98-111. (Pubitemid 34507913)
95. Harrower TP, Tyers P, Hooks Y, Barker RA. Long-term survival and integration of porcine expanded neural precursor cell grafts in a rat model of Parkinson's disease. Exp Neurol 2006; 197:56-69. (Pubitemid 41817221)
96. Mason DW, Charlton HM, Jones AJ, et al. The fate of allogeneic and xenogeneic neuronal tissue transplanted into the third ventricle of rodents. Neuroscience 1986; 19:685-694.
97. Munn DH, Zhou M, Attwood JT, et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 1998; 281:1191-1193. (Pubitemid 28406294)
98. Melchior B, Remy S, Nerriere-Daguin V, et al. Temporal analysis of cytokine gene expression during infiltration of porcine neuronal grafts implanted into the rat brain. J Neurosci Res 2002; 68:284-292. (Pubitemid 34462533)
99. Croxford JL, O'Neill JK, Ali RR, et al. Local gene therapy with CTLA4- immunoglobulin fusion protein in experimental allergic encephalomyelitis. Eur J Immunol 1998; 28:3904-3916.
100. Ideguchi M, Kajiwara K, Yoshikawa K, et al. Local adenovirus-mediated CTLA4-immunoglobulin expression suppresses the immune responses to adenovirus vectors in the brain. Neuroscience 2000; 95:217-226.
101. Martin C, Plat M, Nerriere-Daguin V, et al. Transgenic expression of CTLA4-Ig by fetal pig neurons for xenotransplantation. Transgenic Res 2005; 14:373-384. (Pubitemid 41125388)
102. Nagata H, Ito M, Cai J, et al. Treatment of cirrhosis and liver failure in rats by hepatocyte xenotransplantation. Gastroenterology 2003; 124:422-431. (Pubitemid 36169259)
103. Benoist S, Sarkis R, Barbu V, et al. Survival and functions of encapsulated porcine hepatocytes after allotransplantation or xenotransplantation without immunosuppression. Surgery 2001; 129:606-616. (Pubitemid 32374992)
104. Nagata H, Nishitai R, Shirota C, et al. Prolonged survival of porcine hepatocytes in cynomolgus monkeys. Gastroenterology 2007; 132:321-329. The authors demonstrated a prolonged survival of pig islet xenograft in primates by overcoming humoral and hyperacute rejection in liver transplantation indications. (Pubitemid 46108736)
105. Aoki T, Koizumi T, Kobayashi Y, et al. A novel method of cryopreservation of rat and human hepatocytes by using encapsulation technique and possible use for cell transplantation. Cell Transplant 2005; 14:609-620. (Pubitemid 43053751)
106. Aoki T, Jin Z, Nishino N, et al. Intrasplenic transplantation of encapsulated hepatocytes decreases mortality and improves liver functions in fulminant hepatic failure from 90% partial hepatectomy in rats. Transplantation 2005; 79:783-790. (Pubitemid 40546197)
107. Mai G, Nguyen TH, Morel P, et al. Treatment of fulminant liver failure by transplantation of microencapsulated primary or immortalized xenogeneic hepatocytes. Xenotransplantation 2005; 12:457-464. (Pubitemid 41499804)
108. Yang YG. Application of xenogeneic stem cells for induction of transplantation tolerance: present state and future directions. Springer Semin Immunopathol 2004; 26:187-200.
109. Wang Y, Chen X, Armstrong MA, Li G. Survival of bone marrow-derived mesenchymal stem cells in a xenotransplantation model. J Orthop Res 2007; 25:926-932. (Pubitemid 47046439)
110. Brisby H, Tao H, Ma DD, Diwan AD. Cell therapy for disc degeneration: potentials and pitfalls. Orthop Clin North Am 2004; 35:85-93. (Pubitemid 38153094)
111. Acosta FL Jr, Lotz J, Ames CP. The potential role of mesenchymal stem cell therapy for intervertebral disc degeneration: a critical overview. Neurosurg Focus 2005; 19:E4.
112. Wei A, Tao H, Chung SA, et al. The fate of transplanted xenogeneic bone marrow-derived stem cells in rat intervertebral discs. J Orthop Res 2008; 27:374-379.
113. Takada T, Nishida K, Doita M, Kurosaka M. Fas ligand exists on intervertebral disc cells: a potential molecular mechanism for immune privilege of the disc. Spine 2002; 27:1526-1530. (Pubitemid 34787177)
114. Park JB, Chang H, Kim KW. Expression of Fas ligand and apoptosis of disc cells in herniated lumbar disc tissue. Spine 2001; 26:618-621. (Pubitemid 32231549)
115. Choi C, Benveniste EN. Fas ligand/Fas system in the brain: regulator of immune and apoptotic responses. Brain Res Brain Res Rev 2004; 44:65-81. (Pubitemid 38114759)